利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.015 秒)

    Fused azepinone cyclin dependent kinase inhibitors
    2.
    发明授权
    Fused azepinone cyclin dependent kinase inhibitors 有权
    融合氮杂环磷酸依赖性激酶抑制剂

    公开(公告)号：US06610684B2

    公开(公告)日：2003-08-26

    申请号：US09739534

    申请日：2000-12-14

    申请人： Daniel W. Zaharevitz ,  Rick P. Gussio ,  Ravi K. Jalluri ,  Edward A. Sausville ,  Conrad Kunick ,  Laurent Meijer

    发明人： Daniel W. Zaharevitz ,  Rick P. Gussio ,  Ravi K. Jalluri ,  Edward A. Sausville ,  Conrad Kunick ,  Laurent Meijer

    IPC分类号： C07D48704

    CPC分类号： C07D487/04 ,  C07D495/14

    摘要： A new class of cyclin dependent kinase inhibitors that also have antiproliferative activity in human tumor cell line assays are described. Most of these compounds satisfy the formula wherein A is oxygen or sulfur coupled to the right by a single or double bond; R2 is selected from the group consisting of hydrogen, aryl, lower aliphatic substituents, particularly alkyl and lower alkyl ester; R4-R7 are independently selected from the group consisting of alkoxy, amino, acyl, aliphatic substituents, particularly alkyl, alkenyl and alkinyl substituents, aliphatic alcohols, particularly alkyl alcohols, aliphatic nitriles, particularly alkyl nitriles, cyano, nitro, carboxyl, halogen, hydrogen, hydroxyl, imino, and &agr;, &bgr;, unsaturated ketones; R8-R11 are independently selected from the group consisting of aliphatic substituents, particularly alkyl, alkenyl and alkinyl substituents, particularly lower aliphatic substituents, alipahatic alcohols, particularly alkyl alcohols, alkoxy, acyl, cyano, nitro, epoxy, haloalkyl groups, halogen, hydrogen and hydroxyl; R12 is selected from the group consisting of aliphatic groups, particularly lower alkyl groups, aliphatic alcohols, particularly alkyl alcohols, carboxylic acids and hydrogen. Compositions comprising effective amounts of such compounds also are described. These compounds and compositions can be used in a method for inhibiting the proliferation of living cells in a subject comprising administering an effective amount of the compound(s), or composition(s) comprising the compound(s), to a subject to inhibit the proliferation of living cells, such as neoplastic cells.

    摘要翻译： 描述了一类在人肿瘤细胞系测定中也具有抗增殖活性的细胞周期蛋白依赖性激酶抑制剂。 这些化合物中的大多数满足甲醛，A是通过单键或双键向右连接的氧或硫; R2选自氢，芳基，低级脂族取代基，特别是烷基和低级烷基酯; R 4 -R 7独立地选自烷氧基，氨基，酰基，脂族取代基，特别是烷基，烯基和炔基取代基，脂族醇，特别是烷基醇，脂族腈，特别是烷基腈，氰基，硝基，羧基，卤素， 氢，羟基，亚氨基和α，β，不饱和酮; R8-R11独立地选自脂族取代基，特别是烷基，烯基和炔基取代基，特别是低级脂族取代基，脂肪族醇，特别是烷基醇，烷氧基，酰基，氰基，硝基，环氧基，卤代烷基，卤素，氢 和羟基; R 12选自脂族基团，特别是低级烷基，脂族醇，特别是烷基醇，羧酸和氢。 还描述了包含有效量的这种化合物的组合物。 这些化合物和组合物可用于抑制受试者中活细胞增殖的方法，包括向受试者施用有效量的化合物或包含该化合物的组合物以抑制受试者的抑制 活细胞增殖，如肿瘤细胞。

    USE OF PLASMA HSP90 RELATED TO MALIGNANCY
    6.
    发明申请
    USE OF PLASMA HSP90 RELATED TO MALIGNANCY 有权
    使用等离子体HSP90与恶性肿瘤有关

    公开(公告)号：US20100129829A1

    公开(公告)日：2010-05-27

    申请号：US12515770

    申请日：2007-11-26

    申请人： Edward A. Sausville ,  Angelika M. Burger

    发明人： Edward A. Sausville ,  Angelika M. Burger

    IPC分类号： G01N33/574

    CPC分类号： G01N33/574

    摘要： The present invention concerns diagnosing and/or prognosticating cancer in an individual and/or determining response to a Hsp90-interacting therapy in an individual. In particular, the methods and compositions of the therapy relate to levels of Hsp90-α in plasma. Additional methods concern determining levels of Hsp90-associated molecules.

    摘要翻译： 本发明涉及诊断和/或预测个体中的癌症和/或确定个体中Hsp90相互作用疗法的应答。 特别地，该疗法的方法和组合涉及血浆中Hsp90-α的水平。 另外的方法涉及确定Hsp90相关分子的水平。

    Use of plasma HSP90 related to malignancy
    9.
    发明授权
    Use of plasma HSP90 related to malignancy 有权
    使用血浆HSP90与恶性肿瘤有关

    公开(公告)号：US08580519B2

    公开(公告)日：2013-11-12

    申请号：US12515770

    申请日：2007-11-26

    申请人： Angelika M. Burger ,  Edward A. Sausville

    发明人： Angelika M. Burger ,  Edward A. Sausville

    IPC分类号： G01N33/53

    CPC分类号： G01N33/574

    摘要： The present invention concerns diagnosing and/or prognosticating cancer in an individual and/or determining response to a Hsp90-interacting therapy in an individual. In particular, the methods and compositions of the therapy relate to levels of Hsp90-α in plasma. Additional methods concern determining levels of Hsp90-associated molecules.

    摘要翻译： 本发明涉及诊断和/或预测个体中的癌症和/或确定个体中Hsp90相互作用疗法的应答。 特别地，该疗法的方法和组合涉及血浆中Hsp90-α的水平。 另外的方法涉及确定Hsp90相关分子的水平。